Determining appropriate therapy to treat hyperglycemia in diabetic patients who have renal insufficiency (RI)/chronic kidney disease (CKD) is complicated by the fact that most available agents are cleared by the kidney and thus cannot be used in these patients or must be carefully monitored and frequently adjusted. Unfortunately, the few agents that are suitable for patients with RI/CKD—such as insulin and sulfonylurea—greatly increase the risk of hypoglycemia. Therefore, until recently, options for treating diabetes in patients with RI/CKD have been very limited. The DPP-4 inhibitor, linagliptin, is unique among DPP-4 inhibitors in that it does not require dose reduction in patients with severe renal impairment or the need for frequent assessments of renal function for dose calculation,
Posted on: Sat, 30 Nov 2013 17:37:51 +0000
Trending Topics
Recently Viewed Topics
© 2015